Combined Oral Anticoagulant and Antiplatelet for Atrial Fibrillation and Cerebral Atherosclerosis: A Meta-Analysis.

J Stroke · 2026 · PMC13243853 · PMID 42237625

Europe PMC DOI

hedged sentences

0.0540

closest p · 1.1× alpha

0.1360

boldest claim

The sentences

showed a trendP =0.054so close (0.05 < p ≤ 0.1)

For recurrent ischemic stroke, combination therapy showed a trend towards a higher risk compared to OAC monotherapy (OR, 1.12 [95% CI, 1.00– 1.26]; P =0.054) with moderate heterogeneity observed (I 2 =71.1%) ( Figure 3A ).

also in 53,322 other papers

did not reach statistical significanceP =0.067so close (0.05 < p ≤ 0.1)

For short-term outcomes, the direction of effect for recurrent ischemic stroke was consistent with the primary Peto analysis, favoring combination therapy, but did not reach statistical significance (OR, 0.37 [95% CI, 0.13–1.07]; P =0.067; I 2 =0.0%).

also in 111,027 other papers

a nonsignificant trendP =0.136not close (p > 0.1)

[ 10 ] observed events, revealing a nonsignificant trend favoring combination therapy (OR, 0.44 [95% CI, 0.15–1.30]; P =0.136).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.